FDA's 503B Bulks List Proposal: A Sourced Analysis
On April 30, 2026, the FDA proposed removing three GLP-1 active ingredients from the 503B Bulks List. Here's what the proposal actually says, sourced from the Federal Register.
Drugs: Semaglutide, tirzepatide, liraglutide
Action: Proposed exclusion from 503B Bulks List
FDA's stated basis: "No clinical need" for outsourcing facilities to compound from bulk substances
Comment period: Closes June 29, 2026
What the Proposal Says
The FDA's finding is specific: no current clinical need exists for 503B outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk drug substances when FDA-approved versions are commercially available.1
This is the regulatory mechanism. The 503B Bulks List determines which active ingredients outsourcing facilities may use. Exclusion removes the legal basis for large-scale compounding of these drugs.
The Evidence Cited
Shortage Resolution
Semaglutide: shortage resolved February 2025. Tirzepatide: resolved late 2024. Liraglutide: never on shortage list. The FDA's position is that the original justification for compounding — drug scarcity — no longer exists.2
Adverse Event Data
By early 2025, the FDA had received:3
- 455+ adverse event reports for compounded semaglutide
- 320+ reports for compounded tirzepatide
- Many involving dosing errors from multi-dose vials requiring hospitalization
Quality Allegations
Novo Nordisk litigation alleged impurity levels as high as 86% in some tested compounded products.4 The FDA has separately flagged counterfeit products entering through online channels.
What the Proposal Does NOT Do
| Claim | Reality |
|---|---|
| "All compounding is banned" | No — 503A pharmacies are under separate authority |
| "Takes effect June 29" | No — June 29 is the comment deadline, not enforcement |
| "No more compounded GLP-1s anywhere" | No — patient-specific 503A compounding is a different pathway |
Care Bare Rx · from $199/mo
Compare Provider Options →Compounded medications are not FDA-approved. Paid link
Provider Options
$130/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
$146/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
The Source Summary
The proposal is significant but bounded. It targets 503B outsourcing facilities specifically, not all compounding. The rulemaking timeline extends well beyond June 29. Brand-name alternatives at lower prices (oral Wegovy $149/month) provide a transition pathway. Patients should stay informed but not panic.
Sources
- Federal Register. FDA proposed rule, 503B Bulks List exclusion. Published early May 2026.
- FDA drug shortage database. Semaglutide: resolved Feb 2025. Tirzepatide: resolved late 2024.
- Pharmacy Times. "FDA Moves to Permanently Close the Door on Compounded GLP-1s." May 13, 2026. 455+ and 320+ adverse event reports.
- Novo Nordisk litigation filings, impurity testing allegations.